The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Monitoring response and treatment outcome in patients with chronic phase chronic myeloid leukemia (CML) treated with imatinib.
A. Teitelbaum
Consultant or Advisory Role - Novartis (U)
D. Spencer
Consultant or Advisory Role - Novartis (U)
V. K. Bollu
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
B. Chastek
Consultant or Advisory Role - Novartis (U)
J. Coombs
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
M. Kulakodlu
Consultant or Advisory Role - Novartis (U)
R. Morlock
Consultant or Advisory Role - Novartis (U)